Abstract
Technology provides an unparalleled opportunity to remove barriers to earlier identification and engagement in services for mental and addictive disorders by reaching people earlier in the course of illness and providing links to just-intime, cost-effective interventions. Achieving this opportunity, however, requires stakeholders to challenge underlying assumptions about traditional pathways to mental health care. In this Open Forum, the authors highlight key issues discussed in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) meeting-held October 13-14, 2016, in New York City-that are related to three identified areas in which technology provides important and unique opportunities to advance early identification, increase service engagement, and decrease the duration of untreated mental and addictive disorders.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 590-592 |
| Number of pages | 3 |
| Journal | Psychiatric Services |
| Volume | 69 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2018 |
Funding
The TEAAM-I meeting was supported by grants MH090590 and 5R34MH103835-02 from the National Institute of Mental Health (NIMH) to Dr. Kane and by NIMH travel support for grantees. Support for the meeting was also received from Verily Life Sciences, Donald and Barbra Zucker, and The Zucker Hillside Hospital and Northwell Health. Dr. Baker reports receipt of consulting fees from Pear Therapeutics. Dr. Mohr reports receipt of honoraria from Optum Behavioral Health and ownership interest in Actualize Therapy. Dr. Schlosser has a financial interest in and is an employee of Verily Life Sciences. Dr. Kane reports receipt of consulting fees, honoraria, or grant support from or participation in advisory boards for Alkermes, Eli Lilly, EnVivo Pharmaceuticals (Forum), Forest (Allergan), Genentech, Intracellular Therapies, Janssen Pharmaceutica, Johnson and Johnson, Lundbeck, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda, and Teva; he reports being a shareholder in LB Pharmaceuticals and Vanguard Research Group. The other authors report no financial relationships with commercial interests.
ASJC Scopus subject areas
- Psychiatry and Mental health